Skip to main content
OpenTrials
Completed

NCT Number: NCT04263948

Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform

Pancreatic cancer is a rapidly developing cancer with a poor prognosis. The mFOLFIRINOX protocol has become the standard medical treatment for this pathology. However, mFOLFIRINOX is the cause of severe toxicities including leukoneutropenia, thrombocytopenia, diarrhea, nausea-vomiting, anorexia, asthenia, weight loss and peripheral sensory neuropathy. Therefore, its indication is limited to patients in good general condition. In practice, it is often interrupted upon the occurrence of hematological and/or clinical grade 3-4 toxicities, Remote patient tele-monitoring of symptoms (Patient Reported Outcomes), body weight, circadian rhythms, sleep and activity would allow the identification of early warning signals reflecting deterioration or improvement in the health of these fragile patients, and trigger proactive interventions, while they are outside the hospital. Thus, the MultiDom study proposes a comprehensive tele-monitoring and telecare strategy that would complement standard of care over a 7-weeks period to 42 consenting patients. The patients receive neoadjuvant or first line chemotherapy with mFOLFIRINOX for advanced or metastatic pancreatic cancer at one of four centres in Ile-de-France region (France).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreas Cancer Behavior Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Health Behavior Motor Activity Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Pancreatic Diseases Pancreatic Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinique du Mousseau

Évry, IDF, 91000, France

About this study

MultiDom stands up among the very first prospective patient-entered and multidimensional, multiactor and multicenter study, that assesses the qualitative and quantitative impact of mFOLFIRINOX on the daily life of patients with pancreatic cancer in real time. Main endpoint is the rate of patients undergoing toxicity-related emergency hospitalisations, and the objective is to reduce it to <10%. Telemonitored data-based proactive interventions will expectedly prevent worsening of patients 'health, and maintain their chances of disease control on effective mFOLFIRINOX chemotherapy.

Participating patients have usual follow up and treatments for their disease, but also: wear a chest sensor that measures and teletransmits accelerometry, surface temperature and 3D-orientation every min, weigh themselves daily on a BLE-balance, with immediate weight tele transmission, and fill out electronic PRO questionnaires daily using a telecommunicating tablet.

All data are tele transmitted to an approved health data hub, and automatically analysed for physical activity, sleep, circadian rhythms, symptoms scores trends in real time. Visualization screens and alerts are generated according to preset thresholds, and medical team responses are traced.

Currently recruiting centres:

  • Clinique du Mousseau, Evry, France
  • Hospital Paul Brousse (Assistance Publique-Hôpitaux de Paris), Villejuif, France
  • Clinique St-Jean L'Ermitage, Melun, France
  • Private Hospital of Antony, Antony, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Histological or cytological diagnosis of pancreatic adenocarcinoma

  • Locally advanced or metastatic pancreatic cancer
  • With or without previous surgery (pancreas and / or metastases)
  • Performance status of 0 or 1 according to WHO
  • Age between 18 and 85 years old included
  • No history of prior chemotherapy or radiotherapy
  • Absence of cutaneous or mucosal jaundice or skin pruritus
  • No proven thrombosis
  • Absence of heart disease or other pathology poorly controlled by current treatments
  • Bilirubinemia and alkaline phosphatases <1.5 ULN (with or without stent)
  • Hematological, renal and hepatic laboratory tests authorizing the administration of mFOLFIRINOX
  • Affiliated subject or beneficiary of a social security scheme
  • Patient who freely signed informed consent

Exclusion criteria

  • Immediately resectable pancreatic cancer
  • No histological or cytological evidence of pancreatic adenocarcinoma
  • Performance status> 1 (WHO)
  • Age <18 and> 85 years old
  • Prior administration of chemotherapy or radiotherapy
  • Skin jaundice and / or pruritus
  • Uncontrolled venous or arterial thrombosis
  • Co morbidity not controlled by a specific treatment
  • Biological anomalies contraindicating the administration of one or more drugs which make up FOLFIRINOX
  • Lack of GPRS coverage in the home
  • Patient participating in another clinical study
  • Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
  • Pregnant, lactating or parturient woman
  • Patient hospitalized without consent.

Treatment and study plan

Picado system internet platform and connected objects

Device

The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.

Primary outcomes

  1. Toxicity-related emergency hospitalisation rate

    Time frame: First cycle of treatment of 6 weeks

    The main objective is to assess the toxicities occurring during the 6 weeks following the start of the 1st cycle of FOLFIRINOX in conventional administration in patients benefiting from the PiCADo telemonitoring system.

  2. Rates and grades toxicity and early tumor responses

    Time frame: First cycle of treatment of 6 weeks

    Secondary objectives include rates and grades of toxicity and early tumor responses, as well as PiCADo platform performances and users perceptions.

Sponsors and collaborators

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche

Other

Collaborators

  • Altran
  • Assistance Publique - Hôpitaux de Paris
  • Faculty of Medicine Paris Saclay University

Registry information

Official study title

Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform

Acronym: MULTIDOM

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Feb 11, 2020
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.